In the name of Allah

Induction Ovulation with

Gonadotropins

Nazari L, MD Infertility & IVF fellowship Associated professor OB/GYN Shahid Beheshti University of Medical Sciences



GONADOTROPIN THERAPY



- Introduction into clinical practice in 1961
- Extracted from the urine of postmenopausal women (human menopausal gonadotropins [hMG])
- Ratio of luteinizing hormone (LH) to folliclestimulating hormone (FSH) bioactivity is 1:1
 Central role in ovulation induction



Since 1996, recombinant human FSH (rhFSH, >99 percent purity) has been available

 Recombinant preparations are appealing due to:

- Ease of administration (subcutaneous rather than intramuscular)
- Purity
- Batch-to-batch consistency



Gonadotropin therapy:



- Exogenous gonadotropin: complex and expensive & are best carried out by experienced clinicians
- ✓ FSH, LH, HMG
- Assessment of fallopian tube patency before initiating
- high risk for OHSS







PCOS women who have not ovulated or conceived with weight loss, clomiphene, or letrozole therapy

 Hypogonadotropic anovulatory women with hypopituitarism or women with hypothalamic amenorrhea



•Pretreatment evaluation:



Complete history and physical examination

- Laboratory testing
- Pelvic examination or a pelvic ultrasound to rule out ovarian cysts
- Semen analysis of the partner
- ✓ HSG



Preparations hMG OR FSH



 no differences in clinical pregnancy or livebirth rates for rFSH and urinary-derived gonadotropins

 no differences in the rates of ovarian hyperstimulation syndrome (OHSS) between rhFSH and urinary-derived gonadotropins



Hypogonadotropic hypogonadal women need FSH & LH

 Long-acting rhFSH preparations are currently registered in some countries for use in in vitro fertilization (IVF)



Protocols:

The aim of ovulation induction with gonadotropins: formation of a single dominant follicle

 Because ovarian sensitivity to FSH stimulation varies among individual women, specific treatment and monitoring protocols are needed to achieve development of a single follicle when exogenous gonadotropin is administered



In spontaneous cycles, this is achieved at the beginning of the cycle by a transient increase in serum FSH concentrations above the threshold value



HSJ Window Necruitment selection dominance 10 (Menses) Luteofollicular transition

 Concentrations then decrease due to negative feedback, preventing more than one follicle from undergoing preovulatory development



In the conventional gonadotropin protocol, the starting dose of FSH is 150 international units/day

This regimen is associated with a multiple pregnancy rate of up to 36 percent, and ovarian hyperstimulation occurs in up to 14 percent of treatment cycles



In PCOS:

✓ Low-dose, step-up protocol

Low-dose, step-down protocol









 Low-dose, step-up protocol designed to minimizing excessive stimulation and the risk of development of multiple follicles

- Initial subcutaneous or intramuscular dose of FSH is 37.5 to 75 IU/day
- ✓ Dose be increased only if, after 14 days, no response is documented on ultrasonography
- ✓ 37.5 IU then are given at weekly intervals up to a maximum of 225 IU/day
- hCG can be given to trigger ovulation



 Low-dose, step-down protocol of ovulation induction mimics more closely the physiology of normal cycles

Therapy with 150 IU FSH/day is started shortly after bleeding and continued until a dominant follicle (>10 mm) is seen on transvaginal ultrasonography

✓ Dose is then decreased to 112.5 IU/day followed by a further decrease to 75 IU/day three days later, which is continued until hCG is administered to induce ovulation



Monitoring:



- TVS to measure follicular diameter
- ✓ During late follicular phase
- Every two or three days
- ✓ If three or more follicles larger than 15 mm are present, stimulation should be stopped, hCG withheld, and use of a barrier contraceptive advised in order to prevent multiple pregnancies and ovarian hyperstimulation

Ovulatory triggers:



- Both urinary and recombinant hCG preparations are available
- 250 mcg of recombinant hCG appears to be equivalent to the standard doses of urinary hCG (5000 units)
- •GnRh Agonist
- Recombinant LH



✓ Multiple gestation

Ovarian hyperstimulation syndrome





